The efficacy of methylprednisolone in aconite-induced myelo-optic neuropathy in the rabbit

Citation
It. Kim et al., The efficacy of methylprednisolone in aconite-induced myelo-optic neuropathy in the rabbit, NEURO-OPHTH, 24(1), 2000, pp. 301-310
Citations number
21
Categorie Soggetti
Optalmology
Journal title
NEURO-OPHTHALMOLOGY
ISSN journal
01658107 → ACNP
Volume
24
Issue
1
Year of publication
2000
Pages
301 - 310
Database
ISI
SICI code
0165-8107(2000)24:1<301:TEOMIA>2.0.ZU;2-5
Abstract
Studies in animals indicate that aconitine or aconite has toxic effects on the visual system of a rabbit model. The toxic effects include myelo-optic neuropathy, as proven in the visual evoked cortical potentials (VECP) and h istopathological studies. We investigated the effect of intravenous high-do se methylprednisolone ( MP) on myelooptic neuropathy caused by aconite. The group treated with MP (30 mg/kg, twice a day, for 3 days followed by 15 mg /kg for 3 days) in addition to aconite ( 1.5 ml/kg, equivalent to 0.7 mg/kg of aconitine) was compared with an aconite only-injected group and a norma l control group. In the MP-treated group, increased recovery of onset laten cy, peak latency, and amplitude in VECP was recorded at two weeks ( p<0.05) when comparied with the aconite only-injected group. In comparison with th e normal control group, the MP-treated group showed a significant delay in onset latency at one and two months ( p<0.05). The MP-treated group also sh owed a significant difference in peak latency at all observation periods wh en compared with the aconite only-injected group. However, the amplitude in both the MP-treated group and the aconite only-injected group increased at two months and did not show a significant difference when compared with th e normal control group. Histopathological findings of the myelin sheath in the MP-treated group generally showed less severe damage than in the aconit e only-injected group. The true benefits of high-dose MP were clear within two weeks. The authors conclude that treatment with intravenous high-dose M P immediately after aconite injection may have some beneficial effects on t he aconite-induced myelo-optic neuropathy, although such treatment does not show a definite recovery.